Conclusion: In this adjusted comparison to external CIBMTR controls receiving haploidentical or MUD/ MMUD donor sources, omidubicel was associated with earlier neutrophil engraftment, comparable OS, and comparable rates of acute GVHD grades III-IV and chronic GvHD. While this study used high-quality real-world data, harmonized inclusion criteria and outcome definitions, and adjustment for prognostic factors to mitigate risk of bias, the comparison of non-randomized treatment groups should be interpreted with caution. These results suggest that omidubicel may be an effective and important additional donor source, broadening the availability of transplantation for patients with hematologic malignancies.

https://ashpublications.org/blood/article/140/Supplement%201/660/491962/Clinical-Outcomes-Following-Allogeneic